MEGALOBOX 2: NOMAD to Premiere in April 2021 on TOKYO MX & BS11
1.2.2021 10:30:00 EET | Business Wire | Press release
TMS Entertainment today announced that MEGALOBOX 2: NOMAD , the highly anticipated sequel to the internationally acclaimed anime series MEGALOBOX , will premiere in April 2021 on Japanese television networks TOKYO MX and BS11.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210131005078/en/
teaser visual of Nomad (Graphic: Business Wire)
MEGALOBOX , a series based on Tomorrow’s Joe by Asao Takamori (Ikki Kajiwara) and Tetsuya Chiba, was originally released in 2018 to commemorate the 50th anniversary of the original manga title.
Teaser Trailer and Visuals Revealed
The teaser trailer and visuals have also been revealed ahead of the broadcast.
Watch the teaser now: https://youtu.be/bjl0qMgrugQ
The striking teaser visual, drawn by the director Yo Moriyama, shows Joe standing with his gear covering the body full of scars. Seven years after Joe’s reign as the first Megalonia champion, we now find him calling himself Nomad. The accompanying teaser trailer reveals a glimpse of what had happened to Joe after the fateful match with Yuri in MEGALOBOX.
ABOUT MEGALOBOX 2: NOMAD
In the end, “Gearless” Joe was the one that reigned as the champion of Megalonia, a first ever megalobox tournament. Fans everywhere were mesmerized by the meteoric rise of Joe who sprung out from the deepest underground ring to the top in mere three months and without the use of gear. Seven years later, “Gearless” Joe was once again fighting in underground matches. Adorned with scars and once again donning his gear, but now known only as Nomad…
WEB: https://megalobox.com/
Twitter: https://twitter.com/joe50_megalobox
STAFF
Original Concept: Tomorrow’s Joe
Original Comic Books Created by Asao Takamori, Tetsuya Chiba / Published by Kodansha.
Director / Concept Designer: Yo Moriyama
Scenario: Katsuhiko Manabe, Kensaku Kojima
Character Designer: Ayumi Kurashima
Sub Character Designer: Naomi Kaneda
Music: mabanua
Animation production: TMS Entertainment Co., Ltd.
Produced by MEGALOBOX2 Project
CAST
Joe / NOMAD: Yoshimasa Hosoya
GANSAKU NANBU: Shiro Saito
YURI: Hiroki Yasumoto
SACHIO: Michiyo Murase
© Asao Takamori, Tetsuya Chiba/Kodansha/MEGALOBOX2 project. All Rights Reserved.
About TMS Entertainment
By maintaining a balance of creativity and business production, TMS Entertainment provides a one-stop shop for services from IP creation to consumer satisfaction improvement, centered around its animation production, licensing, and content businesses. TMS Entertainment has continuously produced much-loved anime titles in Japan, including "Lupin the 3rd," "Dr. STONE," and “MEGALOBOX” while connecting its library of over 12,000 episodes across a total of 420 titles to its global business.
WEB: https://www.tms-e.co.jp/global/
Twitter:
https://twitter.com/tmsanime
Facebook:
https://www.facebook.com/AnimeTMS
Instagram:
https://www.instagram.com/tmsanime/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210131005078/en/
Contact information
TMS Entertainment Co., Ltd. Paris Office
International Sales & Licensing
Cinzia Mariani
E-mail: tmsparis@tms-e.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom